Finance

Beta
Lists
Equity sectors
Symbols
Symbols
Price
Change
% Change
Trend
Prev Close
Open
High
Low
Volume
Mkt Cap
SIXB
Materials
SIXB
Materials
SIXB
-०.२१%
१,०९१.५१
-२.३०
-०.२१%
—१,०९३.८११,०९६.५२१,१००.२२१,०९१.५१——
SIXC
Communications
SIXC
Communications
SIXC
+०.२२%
६१०.११
+१.३४
+०.२२%
—६०८.७७६०८.७७६१२.९७६०८.७७——
SIXE
Energy
SIXE
Energy
SIXE
-१.३४%
१,२३७.९८
-१६.८३
-१.३४%
—१,२५४.८११,२५३.०११,२५३.८७१,२२६.३३——
SIXI
Industrials
SIXI
Industrials
SIXI
-०.९३%
१,७४४.७१
-१६.४०
-०.९३%
—१,७६१.१११,७६४.२७१,७६६.८८१,७४४.७१——
SIXM
Financials
SIXM
Financials
SIXM
-०.३७%
६४०.१८
-२.४०
-०.३७%
—६४२.५८६४४.८७६४८.४८६४०.१८——
SIXR
Staples
SIXR
Staples
SIXR
-०.१८%
८४९.५८
-१.५५
-०.१८%
—८५१.१३८५५.६६८५८.७५८४५.५६——
SIXRE
Real estate
SIXRE
Real estate
SIXRE
-०.२३%
२१७.४८
-०.५०
-०.२३%
—२१७.९८२१७.९८२१८.६५२१६.८८——
SIXT
Technology
SIXT
Technology
SIXT
+१.५२%
३,२६०.६९
+४८.८६
+१.५२%
—३,२११.८३३,२२७.२१३,२६८.३८३,२२६.५५——
SIXU
Utilities
SIXU
Utilities
SIXU
-०.६९%
९४२.४५
-६.५३
-०.६९%
—९४८.९८९४८.५८९५७.८३९४१.९७——
SIXV
Health care
SIXV
Health care
SIXV
-०.५२%
१,४६६.८०
-७.७२
-०.५२%
—१,४७४.५२१,४७९.०३१,४८१.०४१,४६६.८०——
SIXY
Discretionary
SIXY
Discretionary
SIXY
+०.२२%
२,३९७.५०
+५.३८
+०.२२%
—२,३९२.१२२,३९६.९५२,४२१.२२२,३८२.३२——
NTLA:NASDAQ
Intellia Therapeutics Inc
US$ १३.२६
-१.६३%
(-०.२२) 1D
US$ १३.२४
-०.१५% (-०.०२०)
After hours
Closed: मे १, १६:००:०० GMT-४  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for NTLA...
Open
US$ १३.३९
High
US$ १३.५४
Low
US$ १२.८०
Mkt. cap
१.७६ अरब
Avg. vol.
३१.५२ लाख
Volume
५८.०१ लाख
52-wk high
US$ २८.२५
52-wk low
US$ ६.८३
EPS
-US$ ३.८१
Beta
१.९९
Shares outstanding
११.८१ करोड
No. of employees
३७७
News stories
From sources across the web
GuruFocus
GuruFocus
·
५ घण्टा पहिले
Intellia Therapeutics (NTLA) Sees Major Purchase by ARK Investme
Investing.com
Investing.com
·
६ घण्टा पहिले
Cathie Wood’s ARK sells AMD stock, buys Roblox and Intellia
Intellia Therapeutics
Intellia Therapeutics
·
९ घण्टा पहिले
Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Stock Titan
Stock Titan
·
१० घण्टा पहिले
43 new Intellia employees get stock awards worth 208,850 shares
Profile
Intellia Therapeutics, Inc. is an American clinical-stage biotechnology company focused on developing novel, potentially curative therapeutics leveraging CRISPR-based technologies. The company's in vivo programs use intravenously administered CRISPR as the therapy, in which the company's proprietary delivery technology enables highly precise editing of disease-causing genes directly within specific target tissues. Intellia's ex vivo programs use CRISPR to create the therapy by using engineered human cells to treat cancer and autoimmune diseases. The CRISPR gene editing system was originally invented by Jennifer Doudna, one of Intellia's scientific founders, and Virginijus Šikšnys. The company has entered into a number of different research and development collaborations with leading and emerging biotechnology companies including Novartis, Regeneron, Avencell, SparingVision, Kyverna, and ONK Therapeutics. Intellia has two in vivo programs in ongoing clinical trials. NTLA-2001 is an investigational CRISPR therapy candidate for the treatment for ATTR amyloidosis currently in Phase 1 studies. Wikipedia
About Intellia Therapeutics Inc
CEOJohn Leonard
Employees३७७
Founded२०१४
Headquartersक्याम्ब्रिज, म्यासेचुसेट्स, संयुक्त राज्य अमेरिका
Sector-
Websiteintelliatx.com
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
२०२५ मार्च
२०२५ जुन
२०२५ सेप्टेम्बर
२०२५ डिसेम्बर
Revenue
१.६६ करोड
१.४२ करोड
१.३८ करोड
२.३० करोड
Cost of goods sold
१०.८४ करोड
८.०५ करोड
७.८९ करोड
७.३६ करोड
Cost of revenue
१०.८४ करोड
८.०५ करोड
७.८९ करोड
७.३६ करोड
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
२.९० करोड
४.३७ करोड
४.६३ करोड
४.८१ करोड
Operating expense
२.९० करोड
४.३७ करोड
४.६३ करोड
४.८१ करोड
Total operating expenses
१३.७४ करोड
१२.४२ करोड
१२.५३ करोड
१२.१७ करोड
Operating income
-१२.०८ करोड
-११.०० करोड
-११.१५ करोड
-९.८७ करोड
Other non operating income
-
-
-
-
EBT including unusual items
-११.४३ करोड
-१०.१३ करोड
-१०.१३ करोड
-९.५८ करोड
EBT excluding unusual items
-११.२२ करोड
-१०.२६ करोड
-१०.४८ करोड
-९.२२ करोड
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-११.४३ करोड
-१०.१३ करोड
-१०.१३ करोड
-९.५८ करोड
Net profit margin
-६८७.६१%
-७१०.८१%
-७३५.१९%
-४१६.१५%
Earnings per share
-१.१०
-०.९८
-०.९२
-०.८३
Interest and investment income
८६.०३ लाख
७४.०२ लाख
६७.१४ लाख
६४.७६ लाख
Interest expense
-
-
-
-
Net interest expenses
८६.०३ लाख
७४.०२ लाख
६७.१४ लाख
६४.७६ लाख
Depreciation and amortization charges
-
-
-
-
EBITDA
-११.८३ करोड
-१०.७५ करोड
-१०.९१ करोड
-९.६३ करोड
Gain or loss from assets sale
-
-
-
५.२७ लाख
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

My tasks
You haven't created a task yet
Your tasks will appear here. Schedule tasks and put Google Finance to work while you're away.
Templates
Watchlist briefing
A daily pre-market analysis of your watchlist
Upcoming Earnings
Upcoming earnings reports in the week
Abnormal Volatility & Volume
Volatility and volume early warning today
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer